Data gathered: November 27
AI Stock Analysis - Caribou Biosciences (CRBU)
Analysis generated August 7, 2024. Powered by Chat GPT.
Caribou Biosciences is a biotechnology company specializing in the development of CRISPR-Cas9 and other genome-editing technologies. The company aims to translate these technologies into transformative therapies for various severe diseases. Founded in 2011, Caribou has been at the forefront of gene-editing research, focusing on both therapeutic and agricultural applications. Despite its innovation, the company faces significant challenges reflected in its financial metrics and market performance.
Stock Alerts - Caribou Biosciences (CRBU)
 |
Caribou Biosciences | November 27 Price is up by 5.5% in the last 24h. |
|
Caribou Biosciences | November 26 Price is up by 21.3% in the last 24h. |
|
Caribou Biosciences | November 26 Employee Rating is up by 2.7% over the last month. |
|
Caribou Biosciences | November 17 AI Score is down by 22.6% in the last couple of days. |
Alternative Data for Caribou Biosciences
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 7 | Sign up | Sign up | Sign up |
| Sentiment | 96 | Sign up | Sign up | Sign up |
| Webpage traffic | 7,000 | Sign up | Sign up | Sign up |
| Employee Rating | 76 | Sign up | Sign up | Sign up |
| Google Trends | 24 | Sign up | Sign up | Sign up |
| Patents | 45 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 3 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 2,423 | Sign up | Sign up | Sign up |
| Twitter Followers | 6,561 | Sign up | Sign up | Sign up |
| Twitter Mentions | 12 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 53 | Sign up | Sign up | Sign up |
| Linkedin Employees | 162 | Sign up | Sign up | Sign up |
About Caribou Biosciences
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally.
| Price | $2.20 |
| Target Price | Sign up |
| Volume | 1,560,000 |
| Market Cap | $183M |
| Year Range | $1.56 - $5.29 |
| Dividend Yield | 0% |
| Analyst Rating | 80% buy |
| Industry | Medical Devices |
In the news
 |
Caribou Biosciences to Participate in Upcoming Investor ConferencesNovember 20 - Yahoo |
 |
Cornercap Investment Counsel Inc. Trims Holdings in Caribou Biosciences, Inc. (NASDAQ:CRBU)November 20 - ETF Daily News |
The Rosen Law Firm, P.A. Announces Proposed Class Action Settlement on Behalf of Purchasers of Common Stock of Caribou Biosciences, Inc. – CRBUNovember 18 - GlobeNewswire |
|
|
Contrasting Sutro Biopharma (NASDAQ:STRO) and Caribou Biosciences (NASDAQ:CRBU)November 13 - ETF Daily News |
|
FY2024 Earnings Forecast for CRBU Issued By Leerink PartnrsNovember 12 - ETF Daily News |
|
CRBU FY2024 EPS Increased by Brookline Capital ManagementNovember 11 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 2M | 10M | -8.4M | -35M | -38M | -0.380 |
| Q2 '24 | 3.5M | 11M | -8M | -38M | -43M | -0.420 |
| Q1 '24 | 2.4M | 15M | -12M | -41M | -46M | -0.460 |
| Q4 '23 | 19M | 9.7M | 9.1M | -35M | -35M | -0.390 |
| Q3 '23 | 24M | 9.7M | 14M | -10M | -15M | -0.120 |
Insider Transactions View All
| Rizvi Syed Ali-aamir filed to sell 59,373 shares at $6.3. January 20 '23 |
| Fischesser Ryan filed to sell 110,366 shares at $10.8. October 7 '22 |
| Kanner Steven filed to sell 302,059 shares at $11.2. August 26 '22 |
| Fischesser Ryan filed to buy 102,264 shares at $2.7. January 12 '22 |
| Fischesser Ryan filed to buy 109,082 shares at $4.1. January 12 '22 |
Similar companies
Read more about Caribou Biosciences (CRBU) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Caribou Biosciences?
The Market Cap of Caribou Biosciences is $183M.
What is the current stock price of Caribou Biosciences?
Currently, the price of one share of Caribou Biosciences stock is $2.20.
How can I analyze the CRBU stock price chart for investment decisions?
The CRBU stock price chart above provides a comprehensive visual representation of Caribou Biosciences' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Caribou Biosciences shares. Our platform offers an up-to-date CRBU stock price chart, along with technical data analysis and alternative data insights.
Does CRBU offer dividends to its shareholders?
As of our latest update, Caribou Biosciences (CRBU) does not offer dividends to its shareholders. Investors interested in Caribou Biosciences should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Caribou Biosciences?
Some of the similar stocks of Caribou Biosciences are Boston Scientific, Edwards Lifesciences, Intuitive Surgical, Medtronic, and Stryker.
.